department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Kimmtrak · pharmadog

pharmadog
drugs
Kimmtrak

drug

patient view →

tebentafusp

Marketedupdated 2mo ago

by $IMCR Immunocore Holdings plc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Kimmtrak

generic

tebentafusp

indication

Metastatic Uveal Melanoma

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 1

tagRecall2 co-mentions · 1 sources

Trials studying tebentafusp

phase2Neoadjuvant Tebentafusp for Uveal Melanomarecruitingn=19
phase2Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanomarecruitingn=18
phase2Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitorsactive not recruitingn=410
phase3Adjuvant Tebentafusp in High Risk Ocular Melanomarecruitingn=290
phase2Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanomarecruitingn=44
phase3Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)recruitingn=540
phase2Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanomarecruitingn=30
phase2Tebentafusp in Molecular Relapsed Disease (MRD) Melanomaactive not recruitingn=850

more trials →